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The benefits of moderate amounts of alcohol for a better health and longer life expectancy
compared with abstinence have been suggested by the findings of numerous studies. However,
controversies have emerged regarding the influence of confounding factors and the systematic
errors that might have been inadvertently disregarded in the early studies. This review includes
a description of the findings of those research studies published in the last 5 years on the effects
of moderate alcohol consumption on all-cause mortality, CVD and inflammation, the immune
system, insulin sensitivity, non-alcoholic fatty liver disease (NAFLD) and cancer. Promising
evidences exist from both animal studies and human clinical trials regarding intermediate end-
points of CHD and insulin sensitivity, such as HDL, adiponectin or fibrinogen. However,
controversies and inconsistent findings exist regarding many of these diseases and related
functions and biomarkers. Further research and human randomised-controlled trials with ade-
quate standardisation of the study conditions are necessary in order to draw a comparison
between studies, establish the causal effect of moderate alcohol intake on disease protection
and reach consensus on the circumstances that allow the recommendation of moderate alcohol
habitual intakes as a strategy for health maintenance.
Alcohol: Moderate consumption: Mortality: CVD: Insulin sensitivity
Moderate alcohol consumption, disease and mortality:
relevant methodological issues in research studies
A substantial amount of observational studies have docu-
mented the complex relationship among alcohol con-
sumption, health preservation and mortality. The U-shaped
relationship between alcohol and death, which shows that
moderate alcohol consumption is associated with lower
mortality than complete abstention or heavy alcohol use,
was first described in 1923(1). Although many studies
since then have repeatedly found that moderate drinkers
have a survival advantage compared with abstainers and
heavy drinkers, controversies have emerged regarding the
importance of confounding factors and the validity of such
results if these are taken into consideration. One thing
seems clear from the beginning, and it is the fact that non-
drinkers are different from alcohol consumers in several
characteristics. One might think of differences in socio-
economic status (differences in social support, education
and wealth) and health conditions (comorbidities, func-
tional capacities, etc.), which are more favourable in
moderate drinkers, as several studies have already
shown(1–4). Current drinkers are usually objectively found
and/or tend to self-report to be in better health than never
drinkers or ex-drinkers, the finding resulting probably from
a ‘selection bias’(5,6). Thus, some authors have spoken
about the systematic error of not excluding from the
abstainers category those people who decrease their alco-
hol consumption as they age and become ill(7).
A recent study performed in 12 500 participants in
the USA Health and Retirement Study showed that
eliminating the confounding effect of traditional and non-
traditional risk factors, such as those commented earlier,
attenuated the protective effect (against all-cause
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mortality) of moderate drinking, but remained statistically
significant (OR 0.72, 95% CI 0.57, 0.91)(4). This study
made a number of other corrections, trying to diminish
additional error sources, and always the mortality OR of
moderate drinkers was decreased in comparison with non-
drinkers. One of the cautions in this study referred to the
‘sick quitter’ hypothesis first described by Fillmore
et al.(7), so that recent quitters were excluded from the
primary results. Despite the encouraging results, there is
still an argument to be made in opposition to the protective
effect of moderate drinking (one drink per day) seen in this
study. Adjusting the regression analysis for all risk factors,
traditional (comorbidities, demographic, smoking and
obesity) and non-traditional, led to a half attenuation of the
alcohol–mortality relationship; this fact suggests that other
factors not accounted for might explain the other half of
the association.
Another study on moderate alcohol intake and risk of
functional decline found that after adjusting for lifestyle-
related variables the strength of the association between
lower mobility disability and moderate alcohol consump-
tion was substantially reduced(8). Likely, the question of
how important are confounding factors not controlled
for in observational studies, could only be answered by
randomised-controlled trials (RCT), which, despite being
complicated because of logistical and ethical matters, seem
to have come to be a priority(4). However, after controlling
for a variety of covariates, several recent publications still
report that those who consume a moderate amount of
alcohol have lower all-cause mortality and CHD mortality
compared with non-drinkers(9,10), which supports the
argument that the relationship between moderate alcohol–
CHD mortality and all-cause mortality is causal.
Another question that deserves attention is the effect of
ethnicity as a factor leading to differences in the effects
of moderate alcohol consumption in observational studies.
A review of recent studies performed in Chinese cohorts
with results adjusted by age, socio-economic status and
lifestyle and/or type of home, shows that the same survival
advantage and the same protection against CVD or cogni-
tive decline is found from moderate alcohol use and
occasional use in this population(5,11). Since occasional use
is not believed to possibly exert any physiological effect,
the result seems to point towards factors different from
alcohol, such as a confounding effect by a general mod-
eration in lifestyle driving the association between alcohol
and health benefits, instead of being a causal effect. On the
other hand, according to a study by Sun et al.(5) the benefit
would be restricted, at best, to old and unhealthy people.
There are, however, genetic differences driven by race and
also different ways of life and environmental factors that
might lead to different results in western and eastern
populations.
Gender-dependent differences appear very frequently in
studies on alcohol and its effects on health and disease. The
differences between men and women who are moderate
alcohol users have been described for multiple outcomes,
such as oxidative stress status(12), brain grey matter decrease
(seen only in males)(13,14) and cognitive performance and
decline (benefits seen only in females)(15). In addition to the
need to differentiate what dose and pattern of consumption is
an average moderate intake in women v. men, the intrinsic
hormonal and physiological characteristics of both sexes
must be considered for a reliable investigation of the possible
mechanisms of alcohol influence on health maintenance and
disease prevention.
A topic of relevance in the current state of investigations
on moderate alcohol intake in human subjects is the effect
of low-to-moderate intakes of alcohol during pregnancy in
neonatal status of the foetus. Some reviews have failed
to find a demonstrable negative effect on variables such
as miscarriage, gestation length, birth weight or small for
gestational age outcomes(16). The authors, however, are
aware that the studies have methodological weaknesses.
Moreover, the interest in the prenatal exposure to toxic
substances derives from their possible health implications
according to the ‘foetal programming’ hypothesis(17).
However, these reviews advise that some retrospective
studies and small prospective studies cannot account for all
confounding factors associated with substance use in
pregnant mothers and suggest that novel approaches and
innovative methods are preferable(17). Individual suscept-
ibility and genotype–exposure interactions have been
addressed in a number of studies in animals(18). A very
recent study on 1258 pregnant women found, in contrast
with previous results, that when controlling for a series of
confounding factors, moderate drinking was related to
lower birth weight (P<0.01) and also with neonatal
asphyxia at trend level (P = 0.06)(19).
Moderate alcohol consumption, inflammation and CVD
The beneficial effects of moderate alcohol consumption on
the cardiovascular system have been extensively discussed
in the literature(20). Several epidemiological studies have
demonstrated an association between moderate intake
of alcohol and reduced CVD risk, including CHD and
ischaemic stroke(21,22). These cardioprotective effects are
not only observed in healthy individuals but also in
patients who suffered from myocardial infarction, stroke or
hypertensive risk(23–25).
Epidemiological, clinical and experimental studies have
indicated that inflammatory mechanisms are involved in
the pathogeneses of CVD mainly in atherosclerosis(26,27).
The initial event of atherosclerosis is the endothelial dys-
function, which is characterised by an imbalance between
vasodilation and vasoconstriction, caused in part by the
increased expression of adhesion molecules, pro-
inflammatory cytokines, pro-thrombotic factors and oxida-
tive stress (reviewed by Sitia et al.(28)). Some inflammatory
markers, such as C-reactive protein (CRP), are used to
monitor the disease process and cardiovascular risk(29).
Moderate alcohol consumption could decrease the risk
of CVD through various mechanisms: increase of HDL,
apoA1 and adiponectin levels, reduction of LDL con-
centration, blood pressure, coronary blood flow, platelet
aggregation, fibrinogen levels and others (reviewed by
Klatsky(20) and Brien et al.(22)). Recent studies have
demonstrated that moderate alcohol consumption can lead
to an improvement of inflammation and this effect could
explain the protective action of alcohol consumption on
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the cardiovascular system(30). Interventional studies on the
effects of alcohol consumption on biological markers
of coronary disease risk have been reviewed(22). They
concluded that the moderate consumption of alcohol can
be protective for CHD since the studies showed increased
levels of HDL and adiponectin and decreased levels of
fibrinogen. Moderate beer consumption for 1 month causes
favourable changes on the blood lipid profile(31). Raum
et al.(32) performed repeated measures of CRP in seventy-
two middle-aged adults during 12 months and observed that
the lowest levels of CRP were found in moderate alcohol
consumers (<16 g/d). Similar results were obtained in
another study(30) where 636 healthy individuals were ana-
lysed and moderate alcohol consumption (20–70 g/d) was
negatively correlated with CRP levels. In addition, daily
alcohol consumption was found to have an apparent
U-shaped association with fibrinogen levels. Moreover,
fibrinogen levels of alcohol consumers were lower than
levels of abstainers in patients who had suffered venous
thrombosis(33). In 26 399 women from the Women’s Health
Study, the main two factors mediating the decreased
CVD risk associated with moderate amounts of alcohol were
lipids and glycated Hb levels; however, inflammatory and
haemostatic factors including intercellular adhesion
molecule-1, fibrinogen and CRP, explained 5% of the
risk reduction(10). Imhof et al.(34) conducted a study
to investigate whether the moderate consumption of
alcoholic (ethanol, beer or red wine) and non-alcoholic
beverages (de-alcoholised beer or red wine and water) could
affect the monocyte migration, an important step in athero-
genesis. They showed that the intake of ethanol or de-
alcoholised red wine (20–30 g ethanol/d) reduced monocyte
migration induced bymacrophage chemoattractant protein-1
or N-formyl-methionyl-leucyl-phenylalanine, but the con-
sumption of all tested beverages did not change the macro-
phage chemoattractant protein-1 receptor expression. The
authors suggested that this inhibition of monocyte migration
could represent one mechanism mediating the reduction of
cardiovascular risk by alcoholic beverages. The population-
based Northern Manhattan Study showed that the brachial
artery flow-mediated dilation was better in moderate alcohol
consumers than non-drinkers(35). A study conducted by
Hamed et al.(36) described that the consumption of 250ml
red wine during twenty-one consecutive days improved the
vascular endothelial function, increasing the migration
and proliferation of endothelial progenitor cells. Moderate
alcohol consumers had higher plasma levels of nitrite and
nitrate than teetotalers with a more favourable lipid profile.
NO in plasma has been involved in the cardioprotective
effect but was considered to have a biphasic role and a dose-
dependent effect regarding the findings of even highest NO
levels and higher lipid-related cardiovascular risk in heavy
drinkers(37). The moderate intake of red wine (100ml daily
for 3 weeks) enhanced circulating endothelial progenitor cell
and plasma levels of NO in healthy subjects while beer
(250ml) and vodka (30ml) consumption did not produce any
effect(38). A study with an experimental model of athero-
sclerosis (induced by infusion of angiotensin II in apoE-
deficient mice) showed that mice treated with a low dose of
ethanol for 28 d exhibited less dilation and fewer ather-
omatous lesions than mice treated with a high dose(39).
Authors discuss that the circulating levels of stromal cell-
derived growth factor-1 could be involved, since the treat-
ment with low-dose ethanol increased these levels.
Although moderate alcohol consumption has a protec-
tive action on the cardiovascular system and related dis-
eases, some of the effects seem to be exclusive for wine
intake. Wine has other components besides ethanol, such
as resveratrol and hydroxytyrosol, which have important
antioxidative and anti-inflammatory effects(40). Several
studies have shown that some beneficial actions of mod-
erate wine consumption on the cardiovascular system are
not observed with other alcoholic beverages(38,41).
Moderate alcohol consumption and the immune system
The interplay between alcohol and the immune function is
dependent upon several factors, including the amount,
frequency and duration of the alcohol administration(42).
Abuse of ethanol has been associated with an increased
incidence and severity of infections in human beings and
experimental animals, which has been attributed to induced
immunosuppression(43–45). But while the effect of exces-
sive alcohol consumption has been extensively studied,
little is known about the consequences of moderate alcohol
consumption on the immune system.
One review on this topic by Romeo et al.(46) published
in 2007 refers to the scarce number of studies reporting
effects on immunity with moderate alcohol consumption to
that date. Two of them report a decreased incidence of
common cold in human subjects(47,48), and others describe
anti-inflammatory effects such as those on adhesion prop-
erties of monocytes(49), fibrinogen(50) and inflammatory
cytokine production(50–52) and the transcription factor
NF-kB(52). Another study by Romeo et al.(53,54) reports an
enhancement in a wide spectrum of immune variables,
from leucocyte counts (only in women), to cytokine pro-
duction and Ig concentrations.
The effect on adhesion molecules has been documented
in a number of studies recently. Modest amounts of alcohol
intake (150ml red wine/d) in an RCT decreased vascular
cell adhesion molecule-1 levels only in females(55). Both
cava (sparkling wine from Catalonia region) and gin
decreased adhesion molecules in a cross-over study with
30 g ethanol during 28 d periods(56). Both alcoholic bev-
erages decreased significantly vascular cell adhesion
molecule-1, P-selectin and E-Selectin and the expression of
Sialyl-Lewis(x) (SLe(x)), while intercellular adhesion
molecule-1 was only decreased after cava intake (all
P<0.05). The effect of cava was also significant for the
expression of both, lymphocyte function-associated anti-
gen-1 and very late activation antigen-4. Polyphenols in
cava might explain the superior anti-inflammatory findings.
Regarding these previous studies, it is necessary to con-
sider that although wine and beer are a source of
alcohol, they also contain other components such as carbo-
hydrates, soluble fibre, minerals and vitamins, as well as
polyphenols(57–59) that also influence the immune system.
Several studies have reported on the potential health
and immune system benefits of xanthohumol, principal
prenylated flavonoid found in beer, and resveratrol,
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a polyphenolic phyto-alexin present in the red wine.
Xanthohumol has important immunosuppressive effects on
T-cell proliferation, development of IL-2 activated killer
cells, cytotoxic T-lymphocytes and production of Th1 cyto-
kines (IL-2, interferon-g and TNFa) and exhibits antioxidant
and anti-inflammatory activity(60). Resveratrol and its deri-
vatives have been shown to have a wide spectrum of
biological activity including anti-tumour(61,62), anti-
oxidant(63) and also anti-inflammatory effects(64). This
compound may interfere with immune activation and cyto-
kine cascades, suppressing interferon-g-mediated biochem-
ical pathways(65), which could be of a great relevance to
interrupt development and progression of some diseases
related to the immune system. Therefore, further studies
focused on moderate alcohol consumption from both
fermented and distilled drinks are necessary to elucidate
their effects on the immune system.
On the other hand, little is known about the effect of
discontinuous moderate consumption of ethanol on immu-
nity. A recent study(66) compared the effect of the dis-
continuous feeding (3 d/week) of a liquid diet containing a
moderate amount of ethanol with that of a continuous
ethanol administration or a control diet on the immune
system in rats. A significant (P<0.001) decrease of splenic
cells’ response to concanavalin A, and of lymph node and
splenic cells’ response to lipopolysaccharide was found in
rats under the discontinuous ethanol regime, when com-
pared with control- or ethanol-chronic rats. Under dis-
continuous ethanol feeding, mean values of lymph node
and splenic CD8(+ ) and CD4(+ )–CD8(+ ) cells
decreased, whereas those of lymph node and splenic T-
cells, and splenic B-cells augmented. In rats chronically
fed with ethanol, splenic mean levels of CD8(+ ) and
CD4(+ )–CD8(+ ) cells increased. Mean plasma prolactin
levels increased by 3.6- and 8.5-fold in rats chronically or
discontinuously fed with alcohol, respectively. These
results suggest that the discontinuous drinking of a mod-
erate amount of ethanol can be more harmful for the
immune system than a continuous ethanol intake. Due to
the scarcity of data in the literature about this subject,
further studies would be necessary, especially considering
that a significant proportion of adolescents and youth tend
to consume alcohol in a discontinuous pattern at weekends.
Various metabolic effects of moderate alcohol
consumption
Insulin sensitivity
The relationship between alcohol consumption and insulin
resistance shows a U-shaped curve: insulin resistance is
minimal in individuals with regular mild-to-moderate
alcohol consumption and increases in both heavy drinkers
and subjects without any alcohol consumption. Improved
insulin sensitivity seems to explain the fact that moderate
alcohol consumption is associated with a decreased risk of
type 2 diabetes in numerous research studies(67–69). Posi-
tive associations between alcohol consumption and insulin
sensitivity are consistently reported in cross-sectional stu-
dies(70–71), but RCT(72–75) as well as studies in patients
with diabetes mellitus(76) report contradictory results.
Moreover, the only study in which a direct measure of
insulin-mediated glucose uptake (the euglycaemic, hyper-
insulinaemic clamp) indicated that moderate alcohol con-
sumption significantly improved insulin sensitivity (43%;
P = 0.02) was performed in patients with type 2 dia-
betes(77). Kim et al.(78) trying to reconcile prior conflicting
findings conducted a study on a group of twenty subjects
who were in the upper tertile of insulin resistance for
individuals with normal glucose tolerance. They performed
the steady-state insulin suppression test before and after
consuming 30 g alcohol for 8 weeks. At best, there was a
trend towards enhanced insulin sensitivity in the total
group of approximately 8%, with a significant improve-
ment of a modest degree in men (approximately 11%;
P = 0.04).
Despite insulin sensitivity itself not improving sig-
nificantly, several molecules involved in energy and mac-
ronutrient metabolism such as adiponectin, ghrelin and the
acylation stimulating protein seem to respond to moderate
alcohol consumption in line with the hypothesised
improvement of insulin sensitivity(79). Moderate alcohol
consumption increased adiponectin and ghrelin, while it
decreased acylation-stimulating protein concentrations in a
group of healthy lean and overweight men. The orexigenic
peptide ghrelin has been recently shown to be required for
alcohol-induced reward, inducing moderate alcohol con-
sumption in mice(80).
Adiponectin
Different RCT with moderate alcohol consumption in the
form of wine, beer or whisky confirmed an increase in
serum adiponectin levels in young men, pre-menopausal,
normal-weight women and middle-aged men and
women(68,75,79,81,82). Sierksma et al.(68) suggested that an
increase in adiponectin could precede changes in insulin
sensitivity with moderate alcohol consumption. Adipo-
nectin is thought to improve insulin sensitivity by
increasing glucose uptake and fatty acid oxidation in
muscle tissue(83).
A study conducted in middle-aged men with abdominal
overweight consuming moderate amounts of alcohol (red
wine) during 4 weeks, showed moderately increased
plasma adiponectin concentration, whereas fat distribution,
serum resistin and insulin sensitivity index were unaf-
fected(75). Changes in adiponectin were not associated with
changes in body weight, fat distribution or insulin sensi-
tivity index, suggesting that other mechanisms mediate the
effect of moderate alcohol consumption on adiponectin
concentrations. Plasma adiponectin concentration increased
by 10% after 28 d of moderate consumption of red wine
compared with de-alcoholised red wine. This increase in
adiponectin is consistent with the 11% increase observed
by Sierksma et al.(68) and two observational studies(84,85).
Lately, another cross-over study in lean and overweight
young men consuming three cans of beer daily, confirmed
an increase in adiponectin with no change in the insulin
sensitivity index. However, this time a positive association
was observed between both variables. According to the
authors of this study, adiponectin may predict changes of
insulin sensitivity, but interventions longer than 3–4 weeks
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may be needed to detect changes of insulin sensitivity
with moderate alcohol consumption(79). On the contrary,
Sierksma et al.(68) found in his cross-over study that
adiponectin increased more in the insulin-sensitive sub-
group than in the insulin-resistant one, despite only the last
subgroup showing a borderline significant increase
(P = 0.11) in insulin sensitivity.
In 2009, Imhof et al.(82) conducted a study with a total
of seventy-two healthy individuals (22–56 years) enrolled
in a cross-over RCT. After washout, two interventions for
3 weeks followed, with another 3 weeks-wash-out between
periods. The subjects were randomly allocated to con-
sumption of ethanol (concentration 12.5%), beer (5.6%) or
red wine (12.5%) equivalent to 30 g ethanol/d for men and
20 g/d for women or the same de-alcoholised beverages or
water. Among women, adiponectin significantly increased
after consuming red wine (29.8%, P<0.05) and increased
among men after ethanol solution (17.4%, P<0.05) and
beer (16.1%, P<0.05). De-alcoholised beverages had no
substantial effect on adiponectin concentrations. In con-
clusion, the authors confirmed that moderate amounts of
ethanol-containing beverages increase serum adiponectin
concentrations, but sex-specific effects might depend on
the type of beverage consumed.
Non-alcoholic fatty liver disease
The effect of alcohol consumption on the liver is con-
troversial. Excessive alcohol consumption and obesity are
known to lead to accumulation of fat in hepatic tissue
and to induce changes in serum liver-derived enzymes.
However, moderate alcohol consumption effects are not
so clear. A protection against the development of hyper-
transaminasaemia among male subjects without other
liver conditions has been found associated with light-to-
moderate alcohol consumption(86).
Non-alcoholic fatty liver disease (NAFLD) is a common
cause of elevated liver enzymes and chronic liver disease
in Western countries. The NAFLD is characterised by
hepatic steatosis in the absence of significant alcohol use or
other known liver disease(87). The term NAFLD comprises
a spectrum of diseases which range from fat accumulation
in hepatocytes with no associated inflammation or fibrosis
(simple steatosis) or steatosis with inflammation to non-
alcoholic steatohepatitis that includes macrovesicular
steatosis, lobular inflammation, balloon degeneration of
hepatocytes and zone 3 pericellular fibrosis(88).
Results from a study including 5599 Japanese asympto-
matic male subjects indicated that the prevalence of fatty
liver (FL) was significantly and independently decreased
by light and moderate alcohol consumption (P = 0.044 and
0.008, respectively)(89). In another study, also in Japanese
population, the major risk factors for FL in Japanese men
were factors related to adiposity, while consistent alcohol
consumption (>21 d/month) was inversely associated with
the prevalence of FL(90). Also in the severely obese, mod-
erate alcohol consumption seems to reduce the risk of
NAFLD, possibly by reducing insulin resistance(91–92).
Conversely, Alatalo et al.(93) showed that increased BMI
and moderate drinking have additive effect on enzymes
reflecting hepatocellular health in the Nordic population. In
their study of 2164 healthy adults, glutamyltransferase
seems to be most sensitive to ethanol intake, while alanine
aminotransferase seems to be the predominant responder to
increasing BMI.
Regarding the relationship of altered liver enzymes
with the risk of type 2 diabetes in the context of varying
habitual alcohol intakes, a prospective study showed that
glutamyltransferase, alanine aminotransferase and daily
alcohol consumption were independently associated with
the risk of type 2 diabetes(94). Moderate daily alcohol
consumption (16.4–42.6 g ethanol/d) decreased the risk of
type 2 diabetes, and higher levels of glutamyltransferase
and alanine aminotransferase increased the risk. At every
level of glutamyltransferase, moderate, but also heavy,
alcohol drinkers ( ‡ 42.7 g ethanol/d) had a lower risk of
type 2 diabetes than non-drinkers. However, the authors do
not mention the possible confounding effect of recent
quitters among the non-drinkers.
A pre-existing condition of hepatic damage seems to
change the response to moderate amounts of alcohol.
He´zode et al.(95) found a relationship between the level of
alcohol intake and the degree of steatosis in chronic
hepatitis C patients, but an interesting finding was the
relationship between histological lesions and steatosis.
They suggested that steatosis might play a role explaining
the aggravation of histological lesions associated with even
moderate alcohol intake in hepatitis C patients. Both heavy
(more than 50 g/d in women and 60 g/d in men) and mod-
erate (21–50 g/d in women and 31–50 g/d in men) alcohol
intake showed a deleterious effect in this setting. Similarly,
with a pre-existing non-alcoholic steatohepatitis condition,
a recent study with rats demonstrated that a moderate
consumption of alcohol can lead to more hepatic inflam-
mation and cell death(96).
Whether the amount of alcohol consumption (light to
moderate), the frequency or both are responsible for the
beneficial effect on NAFLD development is unknown, and
little is known also about the association between alcohol
consumption and FL in women alone. Recently, Moriya
et al.(97) confirmed that the drinking frequency was inver-
sely correlated to the prevalence of ultrasonographically
determined FL and alanine aminotransferase elevation in
men, whereas light and infrequent alcohol consumption
was associated with a low risk of FL in women.
Moderate alcohol consumption and cancer risk
Alcohol consumption has been associated with a variety
of different forms of cancer in man for several centuries.
The evidence linking alcohol drinking to cancer risk has
been reviewed in different occasions, some of them
recently(98–100).
Many epidemiological studies have investigated the
relationship between high alcohol intake and risk of can-
cer; however, there are very few intervention studies
relating the risk of cancer associated with moderate
intakes, with the exception of breast cancer(101).
Several case–control studies derived from measurements
of alcohol intake in women suggest that both, moderate
and excessive alcohol intake, may contribute to the risk of
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breast cancer(102). Results from the Nurses’ Health Study
(1980) in the United States, initially based on 89 538 US
nurses aged between 34 and 59 years, with no history
of cancer, showed that, among the low-to-moderate drin-
kers (5–14 g alcohol daily; three to nine drinks per week),
the age-adjusted relative risk of breast cancer was 1.3
v. non-drinkers(102). Consumption of 15 g alcohol or more
per day was associated with a relative risk of 1.6. Sig-
nificant associations were observed for beer and liquor
when considered separately. Similarly, The National
Institutes of Health–AARP Diet and Health Study
(1995–2003), including 184 418 post-menopausal women
aged 50–71 years, reported that, during an average of 7
years of follow-up, even a moderate amount of alcohol
(>10 g/d) significantly increased breast cancer risk.
And definitely, in a comparison of >35 v. 0 g/d alcohol,
the multivariate relative risks were 1.35 for total breast
cancer, 1.46 for ductal tumours, and 1.52 for lobular
tumours(103).
The mechanism by which alcohol contributes to breast
tumour initiation or progression is yet to be definitively
established. There appear to be multiple mechanisms
by which alcohol may contribute to breast malignancies
or may modulate the behaviour of mammary epithelial and
tumour cells in vivo and in vitro. Mill et al.(104) postulate
three mechanisms by which alcohol may contribute to
breast tumour genesis, progression or aggressiveness. A
common feature of these mechanisms is the increase
in epidermal growth factor receptor tyrosine kinase sig-
nalling(104).
On the other hand, results from some other studies sug-
gest that alcohol may reduce the risk of some cancers such
as rectal cancer(105) and renal cell carcinoma(106). In the
population-based case–control North Carolina Colon Can-
cer Study, moderate alcohol intake was inversely asso-
ciated with distal colorectal cancer. The OR for moderate
alcohol consumption ( £ 14 g/d) was 0.66, whereas the OR
for >14 g/d was 0.93 v. no alcohol intake. Moderate beer
and wine intakes were also inversely associated with this
cancer(105).
Conclusions
In the literature there are a substantial amount of RCT with
moderate alcohol consumption, at least in regular and
occasional alcohol drinkers. Although receiving ethical
permission for such trials with abstainers might seem dif-
ficult, some have already been published, for instance,
among type 2 diabetic subjects(107). Several RCT and their
meta-analysis(22) have shown that intermediate end-points
related to CVD and/or insulin sensitivity, such as HDL,
adiponectin and fibrinogen improve with moderate alcohol
consumption, which are indirect evidence of a causal
protective effect of alcohol. The logistical problems of
performing sufficiently powerful studies, with a large
number of healthy people recruited to be on the rando-
mised-controlled intervention for time enough to assess the
effect of moderate alcohol on variables such as cognitive
decline, functional decline or all-cause mortality, seem
more restraining than the ethical issues.
In summary, most aspects of health and illness reviewed
here are still insufficiently studied in relation with the
advantage of moderate alcohol. Controversy and incon-
sistent findings appear on the effects of moderate alcohol
on insulin sensitivity as derived from RCT, the number of
studies regarding immune modulation is scarce, lack of
positive effects have been reported in most cancer studies
and the effect on the liver is controversial. As a conclusion,
it seems to be too soon to recommend moderate con-
sumption of ethanol as a strategy to promote better health.
Finally, important methodological issues should be con-
sidered in future studies. In this sense, it seems important
to define and standardise what a moderate dose for each
sex is, taking into account age range, pattern of drinking,
health status and lifestyle (i.e. only household elderly or
institutionalised, not both), so that comparisons can be
made between studies.
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